|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2009-8-27
|
|
pubmed:abstractText |
Nonviral gene therapy of chronic degenerative diseases such as Parkinson's disease (PD) is a great challenge as a result of the low tranfection efficiency of nonviral gene vectors. We previously constructed a lactoferrin (Lf)-modified vector, which was demonstrated to be potential for brain gene delivery both in vitro and in vivo. In the present study, this type of vector was applied to load human glial cell line-derived neurotrophic factor gene (hGDNF).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1521-2254
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
754-63
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19554623-Animals,
pubmed-meshheading:19554623-Behavior, Animal,
pubmed-meshheading:19554623-Disease Models, Animal,
pubmed-meshheading:19554623-Gene Therapy,
pubmed-meshheading:19554623-Glial Cell Line-Derived Neurotrophic Factor,
pubmed-meshheading:19554623-Immunohistochemistry,
pubmed-meshheading:19554623-Lactoferrin,
pubmed-meshheading:19554623-Male,
pubmed-meshheading:19554623-Nanoparticles,
pubmed-meshheading:19554623-Neuroprotective Agents,
pubmed-meshheading:19554623-Oxidopamine,
pubmed-meshheading:19554623-Parkinson Disease,
pubmed-meshheading:19554623-Rats,
pubmed-meshheading:19554623-Rats, Sprague-Dawley
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles.
|
|
pubmed:affiliation |
Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai, China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
